Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.
News Item
Multidisciplinary Sciences
Ewen Callaway
Article
Biochemistry & Molecular Biology
Daming Zhou et al.
Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.
Letter
Medicine, General & Internal
Charlotte Manisty et al.
Letter
Medicine, General & Internal
Maria Prendecki et al.
Letter
Medicine, General & Internal
John F. R. Robertson et al.
Article
Biochemistry & Molecular Biology
Constantinos Kurt Wibmer et al.
Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Virology
Federico Gobbi et al.
Summary: Individuals who previously contracted SARS-CoV-2 are expected to have a more rapid and sustained immune response to COVID-19 vaccines, with markedly higher titers of neutralizing antibodies compared to natural infection. A single dose of the vaccine may be sufficient to induce an effective response in previously infected individuals.
Article
Medicine, General & Internal
Victoria Jane Hall et al.
Summary: The study aimed to determine the factors associated with vaccine coverage for two COVID-19 vaccines in the UK and to document the vaccine effectiveness of the BNT162b2 mRNA vaccine among healthcare workers. Results showed that the vaccine can prevent both symptomatic and asymptomatic infections in working-age adults, with a vaccine effectiveness of 70% after the first dose and 85% after the second dose.
Article
Biochemistry & Molecular Biology
Joseph E. Ebinger et al.
Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
Article
Medicine, General & Internal
S. A. Madhi et al.
Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Todd Bradley et al.
Summary: A small study found that antibody responses significantly increased in healthcare workers after receiving a single dose of the SARS-CoV-2 vaccine, including antibodies to spike protein subunits S1 and S2, as well as the receptor-binding domain.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Catherine J. Reynolds et al.
Summary: Vaccination with a single dose of BNT162b2 after prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants. In contrast, individuals without prior infection showed reduced immunity against variants after receiving a single vaccine dose.
Article
Biochemistry & Molecular Biology
Fatima Amanat et al.
Summary: After receiving the SARS-CoV-2 spike mRNA vaccine, individuals showed robust polyclonal antibody responses, with a majority of vaccine-induced antibodies lacking neutralizing activity. However, vaccine-induced RBD binding antibodies may offer substantial protection against viral variants carrying single E484K RBD mutations.
Article
Infectious Diseases
Dora Buonfrate et al.
Summary: The study assessed the antibody response of healthcare workers to the BNT162b2 mRNA COVID-19 vaccine and found that individuals with previous SARS-CoV-2 infection had a strong antibody response after one dose of the vaccine. Healthcare workers infected in March showed a significantly stronger antibody response compared to those infected in November after vaccination.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Despite challenges posed by COVID-19 variants, convalescent individuals receiving mRNA vaccines exhibit robust and long-lasting immune responses against circulating SARS-CoV-2 variants, providing hope for effective control of the pandemic.
Article
Biochemistry & Molecular Biology
Emma Pritchard et al.
Summary: Results from the Office for National Statistics COVID-19 Infection Survey in the UK demonstrate that the ChAdOx1 nCoV-19 and BNT162b2 vaccines reduce the incidence of new SARS-CoV-2 infections by up to 65% with a single dose and up to 80% after two doses, with no significant differences in efficacy observed between the two vaccines.
Article
Multidisciplinary Sciences
Donal T. Skelly et al.
Summary: Vaccination with two doses generates more robust immune responses against emerging SARS-CoV-2 variants, particularly B.1.1.7 and B.1.351, compared to natural infection. High magnitude T cell responses are produced after two vaccine doses, mainly targeting conserved epitopes between the original isolate and the variants.
NATURE COMMUNICATIONS
(2021)
Article
Cell Biology
Daniel Lozano-Ojalvo et al.
Summary: The study found that the second dose of the vaccine increases immunity in naive individuals, while those who previously recovered from COVID-19 reach their peak immunity after the first dose. This suggests that a second dose may not be necessary for individuals who have been infected with SARS-CoV-2 before.
Article
Medicine, General & Internal
Alexis R. Demonbreun et al.
Summary: A single dose of mRNA vaccine can generate high levels of immune response among individuals previously diagnosed with COVID-19, but two doses are needed for most persons without clinical diagnosis of COVID-19 and seronegative individuals.
Article
Medicine, Research & Experimental
Alessio Mazzoni et al.
Summary: The study suggests that COVID-19-recovered individuals may not need a second vaccine dose to further enhance immune response, while naive individuals require a second dose for increased immunity. This indicates that redirecting vaccine doses from COVID-19-recovered individuals to naive individuals could shorten the time to achieve herd immunity.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Letter
Immunology
Ingra Morales Claro et al.
Summary: In December 2020, the B.1.1.7 lineage of SARS-CoV-2 was detected in Sao Paulo, Brazil, with two distinct introductions identified through rapid genomic sequencing. There may be more infections with this lineage in Brazil than officially reported.
EMERGING INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Alba Grifoni et al.